지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
초록· 키워드
오류제보하기
Background: Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, is a limited factor in the treatment of non-small-cell lung cancer (NSCLC) patients. Therefore, ongoing studies are trying to identify EGFR-TKIs-resistant mechanisms and to discover novel therapeutic strategies and targets for NSCLC treatment. Methods: In the present study, the possibility of overcoming intrinsic gefitinib-resistance was examined by regulating the expression of AXL. A natural product-derived antitumor agent, yuanhuadine (YD) was employed to modulate the expression of AXL in the cells. Results: Treatment with YD effectively downregulated AXL expression in AXL-overexpressed gefitinib-resistant H1299 cells. The combination of gefitinib and YD exhibited a synergistic grwoth-inhibitory activity in H1299 cells by downregulation of AXL expression. Conclusions: Based on these findings, AXL was found to be a promising therapeutic target to overcome the intrinsic resistance to gefitinib in NSCLC. Furthermore, YD is able to effectively regulate the expression of AXL and thus it may be applicable as a potential lead compound for the treatment of gefitinib-resistant NSCLC. (J Cancer Prev 2019;24:217-223)
목차
등록된 정보가 없습니다.
참고문헌 (34)
참고문헌 신청
Jemal A / 2011 / Global cancer statistics / CA Cancer J Clin 61:69~90
Ihde DC / 1992 / Chemotherapy of lung cancer / N Engl J Med 327:1434~1441
Ramanathan RK / 1997 / Chemotherapy for advanced nonsmall cell lung cancer: past, present, and future / Semin Oncol 24:440~454
Shepherd FA / 1994 / Treatment of advanced non-small cell lung cancer / Semin Oncol 21(4):7~18
Wang D / 2005 / Cellular processing of platinum anticancer drugs / Nat Rev Drug Discov 4:307~320
Ihde DC / 1992 / Chemotherapy of lung cancer / N Engl J Med 327:1434~1441
Ramanathan RK / 1997 / Chemotherapy for advanced nonsmall cell lung cancer: past, present, and future / Semin Oncol 24:440~454
Shepherd FA / 1994 / Treatment of advanced non-small cell lung cancer / Semin Oncol 21(4):7~18
Wang D / 2005 / Cellular processing of platinum anticancer drugs / Nat Rev Drug Discov 4:307~320
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Inhibition of Ubiquitin-specific Peptidase 8 Suppresses Growth of Gefitinib-resistant Non-small Cell Lung Cancer Cells by Inducing Apoptosis
대한암예방학회지
2015 .01
-
The Role of Brain Radiotherapy Before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung Cancer
Cancer Research and Treatment
2023 .04
-
Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned
Cancer Research and Treatment
2015 .01
-
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
Cancer Research and Treatment
2017 .01
-
Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
Tuberculosis and Respiratory Diseases
2016 .01
-
Animal models and therapeutic molecular targets of lung cancer
한국실험동물학회 학술발표대회 논문집
2019 .01
-
miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer Cells by Targeting USP37
Cancer Research and Treatment
2022 .04
-
비소세포폐암 줄기세포에서 로즈마린산의 항증식 효과
생약학회지(Korean Journal of Pharmacognosy)
2024 .09
-
Low-dose Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Cell Free EGFR mRNA Expression and Implications for Survival and Metastasis in Non-Small Cell Lung Cancer Cases
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Characterization of intracellular Ca2+ mobilization in gefitinib-resistant oral squamous carcinoma cells HSC-3 and -4
International Journal of Oral Biology
2021 .12
-
Combination Therapy of Gefitinib and Korean Herbal Medicines Could be a Beneficial Option for Patients with Non-Small-Cell Lung Cancer
Journal of Pharmacopuncture
2016 .01
-
Current status and future perspectives of liquid biopsy in non-small cell lung cancer
Journal of Pathology and Translational Medicine
2020 .01
-
Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer
Cancer Research and Treatment
2022 .01
-
The Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Receiving Gefitinib
Tuberculosis and Respiratory Diseases
2015 .01
-
Growth inhibition by metformin in YD-38 oral cancer cells derived from Korean
Oral Biology Research
2017 .01
-
Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
Cancer Research and Treatment
2019 .01
-
비소세포폐암의 표적 치료
대한내과학회지
2020 .04
-
EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
Cancer Research and Treatment
2019 .01
-
Clinical Characteristics and Continued Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Administration in EGFR-Mutated Non-small Cell Lung Cancer with Skeletal Metastasis
Cancer Research and Treatment
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0